Locust Walk Insights
SUBSCRIBE TO OUR INSIGHTS
LOCUST WALK INSIGHTS
Crossover Evolution: The Evolving Role of the Crossover Financing Round
The Covid-19 pandemic was the biggest biopharma news of 2020. It may be hard to remember now, but in March of last year, biotech indices had quickly nose-dived, along with the broader market, as the reality of the pandemic became...
2021 Q1 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Q1 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal...
Boston Business Journal: Life sciences firm Locust Walk’s plans for its $175M SPAC
Geoff Meyerson co-founded Locust Walk, a Boston-based life sciences consulting firm, on Sept. 15, 2008, the same day that Lehman Brothers filed for bankruptcy and Merrill Lynch sold itself to Bank of America. Meyerson said he “figured the world didn’t need another...
Locust Walk 2020 Year End Report
Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our 2020 Year End Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal...
Doubling Down: The Power of Asset Diversification in a Time of Robust Access to Capital
Q3 Report: Global Trends in Biopharma Transactions
Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our Q3 2020 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal landscape. ...
Panel Recording! Knocking At The Door: Challenges Women Face With Biopharma Boards
BIO (Biotech Innovation Organization) collected a survey in January of 2020 to better understand the current demographics of biopharma companies. Responses to their questions on representation indicate that the number of women...
Biopharma’s COVID Capital Comeback – A Whitepaper
What a difference a few months can make – especially during a pandemic. Heading into 2020, biopharma looked like it would be typecast in its typical election year role: the big business scapegoat for everything that’s wrong in health care. There had been the usual big...
Live Panel: The Unexpected IPO Boom for Biopharma in Q2
Locust Walk is partnering with Applied Molecular Transport, Forma Therapeutics, and Goodwin for a live panel on Thursday, July 23rd from 1-2 pm EST entitled "The Unexpected IPO Boom for Biopharma in Q2." CLICK HERE TO REGISTER Q2 saw a boom in IPOs, while many...
Q2 2020 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q2 2020 Report applies the latest data to analyze current activities in the life science deal landscape.
Live Panel: Brave New World: Challenges from the East, Asia Biopharma, and Response to COVID-19
Locust Walk is partnering with Santen Pharmaceutical Co., Ltd. CBC Group, and Goodwin to bring together a panel on Wednesday, July 1st, at 6 pm EST, entitled "Brave New World: Challenges from the East, Asia Biopharma, and Response to COVID-19." Please join us for a...
A Brave New World: Japan Pharma and COVID-19
COVID-19 or SARS Cov-2 to be precise, has changed the world in many regards. From the way we work, to the way we do business as well as to even what used to be the simplest thing – chatting over coffee. Now everything, or at least for the time being, is either via...
Deal Makers of Japan, Volume 2
We are pleased to present the second series of the Deal Makers of Japan - Exclusive Interviews with Japan’s best dealmakers. We released our inaugural edition March 2020 and have received numerous comments from biotech/biopharma companies around the world.
Panel Recording on 6.11: Accessing Capital in the Time of COVID
Danforth Advisors, Locust Walk, and Mintz joined on Thursday, June 11th from 2-3pm EST for the panel, "Accessing Capital in the Time of COVID: Challenges, Opportunities, and Best Practices." During the hour, the panel discussed How COVID-19 impacted the capital...
Panel Recording on 5.7: Biopharma Deal Maker’s Guide to Strategic Partnerships
Thank you to all that joined us on Thursday, May 7th for our live panel discussion where we took a deep dive into biopharma deal marker's best practices for strategic partnerships. Listen to the recording. Please stay tuned for more live panels and webinars in the...